3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
4
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Chronic-Phase
1
Interventions
Observation
21
Blood Specimen Collection
20
Drug Therapy
13
Surveys and Questionnaires
8
Surgical Procedures, Operative
8
Immunotherapy
7
Immune Checkpoint Inhibitors
7
Positron Emission Tomography Computed Tomography
5
Hematologic Tests
5
Watchful Waiting
4
Neoadjuvant Therapy
4
Fluorodeoxyglucose F18
4
Bevacizumab
4
darolutamide
3
Tyrosine Kinase Inhibitors
3
Therapeutics
3
Standard of Care
3
Radiotherapy
3
Indocyanine Green
3
Imatinib Mesylate
3
Endoscopic Mucosal Resection
3
Docetaxel
3
Cyclophosphamide
3
Capecitabine
3
Artificial Intelligence
3
tislelizumab
2
pertuzumab
2
palbociclib
2
obinutuzumab
2
nilotinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Observational
×
asciminib
×
Clear all
NCT07091019
2025-07-29
ASC4REAL-2
Novartis
Not yet recruiting
1,000 enrolled